Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
31 Results for "
LLC
" in MedChemExpress (MCE) Product Catalog:
Products (31)
31 Results for "LLC" in MCE Product Catalog:
3
3 Cited Publications
Cat. No.: HY-U00433A
CAS No.: 2448414-54-6
Target:
Research Areas:
JMV 2959 hydrochloride is a growth hormone secretagogue receptor type 1a (GHS-R1a) antagonist with an IC50 of 32±3 nM in LLC-PK1 cells.
1
Category:
Flavonols Plant Flavonoids Monophenols Phenols Other Families Extract Disease Research Fields Inflammation/Immunology
Target:
1
Cat. No.: HY-154487
CAS No.: 25637-84-7
Target:
Research Areas:
Glycerol dioleate is a lipid capable of forming Lyotropic Liquid Crystal (LLC). When formulated with phosphatidylcholine and exposed to aqueous media, glycerol dioleate constructs an inverted hexagonal (HII) phase structure with sustained-release properties. The in-situ forming gel prepared by optimizing glycerol dioleate with phosphatidylcholine and N-methyl-2-pyrrolidone enables stable release of Risperidone (HY-11018) for up to 60 days in vitro and in vivo. Glycerol dioleate causes minimal side effects in rabbits, making it an ideal carrier component for the development of antischizophrenia agents .Note: Lyotropic liquid crystals (Lyotropic Liquid Crystal, LLC) are ordered fluid phases self-assembled by amphipathic molecules (e.g., lipids, surfactants) in solvents (usually water) at specific concentrations .
Cat. No.: HY-161574
CAS No.: 3061315-33-8
Target:
Research Areas:
LLC0424 is a potent and selective cereblon-based PROTAC nuclear receptor-binding SET domain-containing 2 (NSD2) degrader. LLC0424 effectively degraded NSD2 with a DC50 of 20 nM in RPMI-8402 cells. LLC0424 selectively induces NSD2 degradation in a cereblon- and proteasome-dependent fashion. (Blue: CRBN ligand (HY-14658), Black: linker (HY-40002); Pink: NSD2 inhibitor (HY-161575)) .
Cat. No.: HY-W158030
CAS No.: 5418-95-1
Synonyms: 2GBI
Research Areas:
2-Guanidinobezimidazole (2GBI) is a NLRP3 agonist with a KD of 1.29 μM and a selective state-dependent HVCN1 blocker. 2-Guanidinobezimidazole directly binds NLRP3’s LRR domain, enhances NLRP3-ASC and NLRP3-NEK7 interactions, and drives NLRP3 inflammasome activation. 2-Guanidinobezimidazole can be used for the research of LLC lung carcinoma, B16F10 melanoma and ischemic stroke .
Cat. No.: HY-162275
CAS No.: 861224-48-8
Research Areas:
JMJD1C-IN-1 is an orally active and selective inhibitor of JMJD1C (IC50 = 0.59 μM, Kd = 1.96 μM). JMJD1C-IN-1 inhibits the binding of JMJD1C to H3K9me2 peptide substrate in the HTRF assay (IC50 = 1.47 μM). JMJD1C-IN-1 disrupts intratumoral regulatory T (Treg) cell fitness by dual mechanisms: promoting H3K9me2 accumulation to downregulate PD1 expression and reducing STAT3 demethylation to enhance STAT3 activation. JMJD1C-IN-1 demonstrates dose-dependent antitumor efficacy in multiple mouse tumor models (MCA205 fibrosarcoma, B16-F10 melanoma, LLC lung cancer, Hepa1-6 hepatocellular carcinoma, CT26 colorectal cancer). JMJD1C-IN-1 can be used for the study of tumor immunotherapy by selectively targeting intratumoral Treg cells .
Cat. No.: HY-162540
Target:
Research Areas:
LLC355 is a discoidin domain receptor 1 (DDR1) ATTEC degrader with a DC50 of 150.8 nM. LLC355 induces DDR1 protein degradation via lysosome-mediated autophagy. LLC355 inhibits the tumorigenicity, migration and invasion abilities of cancer cells, and induces apoptosis. LLC355 is applicable to research related to non-small cell lung cancer and pancreatic cancer .
Cat. No.: HY-161575
Research Areas:
NSD2 ligand 1 is a NSD2 ligand. NSD2 ligand 1 can be used for synthesis of LLC0424 (HY-161574) (a PROTAC NSD2 degrader) .
Cat. No.: HY-125664
CAS No.: 480439-84-7
Target:
Cat. No.: HY-169122
Target:
Research Areas:
LLC1 is an Amiloride (HY-B0285) derivative with cytotoxicity against breast cancer cells, particularly those resistant to treatment. The IC50 values of LLC1 for MCF7, MCF7 MX-100, MCF7 TS, MCF7 TR-1, and MCF7 TR-5 are 13, 12, 25, 26, and 19 mM, respectively. LLC1 shows potential for research in the field of cancer therapy .
Cat. No.: HY-114749
CAS No.: 93752-54-6
Category:
Target:
Cat. No.: HY-122379
CAS No.: 81426-17-7
Target:
Cat. No.: HY-161576
CAS No.: 2636798-54-2
Research Areas:
Thalidomide-Pip-N-boc is a conjugate of E3 ligase ligand and linker. Thalidomide-Pip-N-boc is utilized for synthesis of PROTAC Degrader LLC0424 (HY-161574) .
Cat. No.: HY-122783
CAS No.: 149655-52-7
Target:
Cat. No.: HY-160021
CAS No.: 2241769-59-3
Target:
Research Areas:
RORγt agonist 4 (compound 14) is a potent and selective agonist of RORγt. RORγt agonist 4 significantly enhances metabolic stability. RORγt agonist 4 improves the situation of tumor models of mouse B16F10 melanoma and LLC lung adenocarcinoma .
Cat. No.: HY-185557
CAS No.: 3063448-59-6
Target:
Research Areas:
LLC0424N is a negative control compound designed by methylating the thalidomide moiety of LLC0424 (HY-161574). LLC0424N shows does not induce NSD2 degradation and inhibit growth of acute lymphoblastic leukemia cells with NSD2 mutation. LLC0424N can be used for the research of acute lymphoblastic leukemia .
Cat. No.: HY-149982
CAS No.: 2126853-16-3
Research Areas:
IDO1-IN-22 (Compound 3) is a IDO1 inhibitor (biochemical hIDO1 IC50: 67.4 nM, HeLa hIDO1 IC50: 17.6 nM). IDO1-IN-22 has excellent antitumor efficacy in LLC xenograft model, as well as desirable pharmacokinetic (PK) profile .
Cat. No.: HY-172951
Antitrypanosomal agent 23 is an antitrypanosomal agent. Antitrypanosomal agent 23 has activity against intracellular amastigotes of T. cruzi in LLC-MK2 and C2C12 cells (IC50: 0.10 and 0.11 μM). Antitrypanosomal agent 23 is a weak inhibitor of Recombinant trans-sialidase from T. cruzi (TcTS) (IC50: 1.1 mM) .
Cat. No.: HY-D3200
CAS No.: 3112200-59-3
Target:
Research Areas:
Dns-LLC is a cell-permeable Cu +-selective fluorescent probe that forms a 1:1 complex with Cu +. The thiol group of Dns-LLC plays a key binding role, while the sulfonamide and amide groups jointly contribute to the stabilization of the complex. Upon binding to Cu + in aqueous buffer solutions, Dns-LLC generates a turn-on fluorescence response, which can be used for the detection of Cu + in the Golgi apparatus .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
